Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The FDA has approved Contrave for long-term weight management in adults who meet specific BMI requirements: A body mass index (BMI) of 30 kg/m or higher (obese), or A BMI of 27 kg/m or higher (overweight), plus at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol (dyslipidemia) Contrave can also be taken by: Adults looking for mild to moderate weight loss People who also have depression or binge eating disorder, Contrave may help with mood and cravings Those who prefer taking a daily pill instead of weekly injections Only approved for use in adults (18 and older) If you prefer tablets over injections or do not require significant weight loss (above 10%), Contrave may be right for you
The safety of IV therapy for the skin is contingent on factors like the drips composition and a persons health status
Combating fibrosis Endometriosis lesions develop fibrotic (scar-like) tissue that causes adhesions, organ dysfunction, and pain
Phase 2 Metabolic Benefits Beyond weight loss, retatrutide improved cardiometabolic markers: Blood pressure: Systolic BP decreased 7.4 mmHg (12mg dose) Triglycerides: Reduced 27% from baseline Fasting glucose: Decreased 13.8 mg/dL HbA1c: Reduced 0.4% (in participants without diabetes) TRIUMPH-4: First Phase 3 Results (December 2025) TRIUMPH-4 was the first Phase 3 trial to report
Walking remains one of the best exercises for digestive health
Some minor side effects, such as nausea or injection site reactions, may occur but typically resolve on their own
